Scholar Rock (NASDAQ:SRRK) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Scholar Rock (NASDAQ:SRRK) issued its earnings results on Thursday. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01), FiscalAI reports. During the same period last year, the business posted ($0.67) earnings per share.

Here are the key takeaways from Scholar Rock’s conference call:

• FDA accepted Scholar Rock’s BLA for apitegromab to treat children and adults with SMA and assigned a PDUFA action date of September 30, 2026, creating a clear potential approval catalyst.
• The FDA completed an unannounced re‑inspection of the Catalent, Indiana fill–finish site and now has up to 90 days to classify the facility, leaving regulatory timing uncertainty that could affect approval pacing.
• Scholar Rock included a second U.S. fill–finish facility in the resubmitted BLA and reports that all required drug product from that site has been filed, with ample commercial supply expected in early Q3 ahead of the PDUFA date.
• The company exited Q1 with $480 million in cash and marketable securities, drew an additional $100 million from its debt facility and $98 million from ATM proceeds, and retains options (additional draw and PRV monetization) to further strengthen the balance sheet.
• Pipeline momentum continues with enrollment in the OPAL infant/toddler SMA study, a planned mid‑year start of the phase II FORGE trial in FSHD, encouraging subcutaneous apitegromab phase I data, and ongoing phase I dosing of SRK‑439.

Scholar Rock Stock Up 4.2%

Shares of Scholar Rock stock traded up $1.94 during midday trading on Friday, reaching $48.39. 1,049,039 shares of the company’s stock traded hands, compared to its average volume of 1,331,426. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.95 and a current ratio of 6.95. Scholar Rock has a 52 week low of $27.07 and a 52 week high of $51.63. The company’s 50 day simple moving average is $46.15 and its 200 day simple moving average is $43.00. The company has a market cap of $5.77 billion, a price-to-earnings ratio of -14.11 and a beta of 0.70.

Insider Activity

In other news, COO Keith Woods sold 10,220 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $506,605.40. Following the completion of the sale, the chief operating officer owned 620,055 shares in the company, valued at approximately $30,736,126.35. This represents a 1.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Junlin Ho sold 9,580 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total value of $445,757.40. Following the transaction, the general counsel directly owned 241,545 shares in the company, valued at approximately $11,239,088.85. This represents a 3.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 102,736 shares of company stock valued at $4,977,900. Corporate insiders own 13.30% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Large investors have recently added to or reduced their stakes in the stock. CIBC Bancorp USA Inc. bought a new position in shares of Scholar Rock in the third quarter valued at approximately $322,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Scholar Rock during the 4th quarter worth $308,000. Virtus Investment Advisers LLC boosted its holdings in shares of Scholar Rock by 66.2% during the 4th quarter. Virtus Investment Advisers LLC now owns 5,676 shares of the company’s stock worth $250,000 after buying an additional 2,261 shares during the period. Cibc World Markets Corp acquired a new position in Scholar Rock in the 4th quarter valued at $240,000. Finally, Jump Financial LLC bought a new position in Scholar Rock in the 4th quarter worth $235,000. Institutional investors own 91.08% of the company’s stock.

Analysts Set New Price Targets

SRRK has been the subject of a number of recent analyst reports. Citigroup increased their price target on Scholar Rock from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Barclays raised their target price on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday. JPMorgan Chase & Co. boosted their price target on shares of Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a report on Monday, March 16th. Finally, Truist Financial upped their price target on shares of Scholar Rock from $44.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Five research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $56.00.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).